Intraperitoneal biotherapy of malignant peritoneal effusions in ovarian cancer patients

Malignant peritoneal effusions often arise in patients with of ovarian cancer. They are dangerous complication of cancer. Intraperitoneal chemotherapy isn’t always effective and causes side effects. Intraperitoneal interleukin-2 (IL-2) and IL-2 / lymphokine activated killers (LAK) biotherapy is char...

Full description

Saved in:
Bibliographic Details
Published inOpukholi zhenskoĭ reproduktivnoĭ sistemy no. 3-4; pp. 169 - 172
Main Authors К. S. Titov, A. N. Gritsai, L. V. Demidov, L. M. Rodionova, M. V. Kiselevsky, M. V. Mosina
Format Journal Article
LanguageRussian
Published ABV-press 01.07.2014
Subjects
interleukin-2
intraperitoneal biotherapy
lak-cells
malignant peritoneal effusions
ovarian cancer
Online AccessGet full text

Cover

More Information
Summary:Malignant peritoneal effusions often arise in patients with of ovarian cancer. They are dangerous complication of cancer. Intraperitoneal chemotherapy isn’t always effective and causes side effects. Intraperitoneal interleukin-2 (IL-2) and IL-2 / lymphokine activated killers (LAK) biotherapy is characterised of high efficacy in ovarian cancer patients with malignant peritoneal effusions. The objective effect was 82,6 % аnd 72,0 % accordingly. These results suggest that intraperitoneal biotherapy allows to expand possibilities of malignant peritoneal effusions treat- ment in ovarian cancer patients.
ISSN:1994-4098
1999-8627
DOI:10.17650/1994-4098-2012-0-3-4-169-172